The short version of clinical development fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-09-08. Anything still debated is marked as such rather than presented as settled.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid metabolism |
| Preclinical effect | Increased fatty acid oxidation | Observed in rodent studies |
| Key safety signal | Tumors in rodents after long-term exposure | Contributed to halted clinical development |
| Human trial status | No approved product; development stopped | Limited short-term metabolic data |
| Sport regulatory status | Prohibited at all times | WADA hormone and metabolic modulators class |
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
The National Institute for Occupational Safety and Health (NIOSH) is the leading United States federal agency conducting research and providing guidance on the occupational safety and health implications and applications of nanomaterials. Early scientific studies have indicated that nanoscale particles may pose a greater health risk than bulk materials due to a relative increase in surface area per unit mass. Increase in length and diameter of CNT is correlated to increased toxicity and pathological alterations in the lungs. The biological interactions of nanotubes are not well understood, and the field is open to continued toxicological studies. It is often difficult to separate confounding factors, and since carbon is relatively biologically inert, some of the toxicity attributed to carbon nanotubes may be instead due to residual metal catalyst contamination. In previous studies, only Mitsui-7 was reliably demonstrated to be carcinogenic, although for unclear/unknown reasons. Unlike many common mineral fibers (such as asbestos), most SWCNTs and MWCNTs do not fit the size and aspect-ratio criteria to be classified as respirable fibers. In 2013, given that the long-term health effects have not yet been measured, NIOSH published a Current Intelligence Bulletin detailing the potential hazards and recommended exposure limit for carbon nanotubes and fibers. The U.S.
=== 5 July === One person was killed in a Russian airstrike in Donetsk Oblast. In Russia, the governor of Rostov Oblast claimed that ten drones were shot down, causing a fire in Rostov-on-Don. The governor of Krasnodar Krai claimed that a child was killed in a drone attack in Primorsko-Akhtarsk.
=== Wound sterility === Wound sterility, or degree of contamination of a wound, is a critical consideration when evaluating a wound. In the United States, the CDC's Surgical Wound Classification System is most commonly used for classification of a wound's sterility, specifically within a surgical setting. According to this classification system, four different classes of wound exist, each with their own postoperative risk of surgical site infection:
Sources: en.wikipedia.org
=== Gas chromatography === After extracting rocks or live samples with organic solvents, tetrahymanol, gammacerane, and other lipids can be separated using gas chromatography. This technique separates molecules based on their polarity and size, which both inversely affect boiling point. As a compound's boiling point increases, it spends more time as a condensed liquid in the bonded liquid stationary phase of the GC column. More volatile compounds will partition into the gaseous mobile phase and have a short elution time. Before injection onto the chromatographic column, the alcohol substituent on tetrahymanol is acetylated with acetic anhydride, allowing it to volatilize and enter the GC.
In the 1980s, Wächtershäuser and Karl Popper postulated the iron–sulfur world hypothesis for the evolution of pre-biotic chemical pathways. It traces today's biochemistry to primordial reactions which synthesize organic building blocks from gases. Wächtershäuser systems have a built-in source of energy: iron sulfides such as pyrite. The energy released by oxidising these metal sulfides can support synthesis of organic molecules. Such systems may have evolved into autocatalytic sets constituting self-replicating, metabolically active entities predating modern life forms. Experiments with sulfides in an aqueous environment at 100 °C produced a small yield of dipeptides (0.4% to 12.4%) and a smaller yield of tripeptides (0.10%). However, under the same conditions, dipeptides were quickly broken down. Several models postulate a primitive metabolism, allowing RNA replication to emerge later. The centrality of the Krebs cycle (citric acid cycle) to energy production in aerobic organisms, and in drawing in carbon dioxide and hydrogen ions in biosynthesis of complex organic chemicals, suggests that it was one of the first parts of the metabolism to evolve. Concordantly, geochemists Szostak and Kate Adamala demonstrated that non-enzymatic RNA replication in primitive protocells is only possible in the presence of weak cation chelators like citric acid. This provides further evidence for the central role of citric acid in primordial metabolism.
RBR (Reduced Bit Rate): 1.62 Gbit/s bandwidth per lane (162 MHz link symbol rate) HBR (High Bit Rate): 2.70 Gbit/s bandwidth per lane (270 MHz link symbol rate) HBR2 (High Bit Rate 2): 5.40 Gbit/s bandwidth per lane (540 MHz link symbol rate), introduced in DP 1.2 HBR3 (High Bit Rate 3): 8.10 Gbit/s bandwidth per lane (810 MHz link symbol rate), introduced in DP 1.3 DisplayPort 2.0 uses 128b/132b encoding; each group of 132 transmitted bits represents 128 bits of data. This scheme has an efficiency of 96.96%. In addition, a small amount of overhead is added for the link layer control packet and other miscellaneous operations, resulting in an overall efficiency of ≈96.7%. The following transmission modes are added in DP 2.0:
==== MeSH D12.125.068 – amino acids, basic ==== MeSH D12.125.068.050 – arginine MeSH D12.125.068.050.075 – argininosuccinic acid MeSH D12.125.068.050.095 – benzoylarginine-2-naphthylamide MeSH D12.125.068.050.100 – benzoylarginine nitroanilide MeSH D12.125.068.050.400 – homoarginine MeSH D12.125.068.050.525 – ng-nitroarginine methyl ester MeSH D12.125.068.050.587 – nitroarginine MeSH D12.125.068.050.650 – omega-n-methylarginine MeSH D12.125.068.050.900 – tosylarginine methyl ester MeSH D12.125.068.060 – asparagine MeSH D12.125.068.330 – glutamine MeSH D12.125.068.330.700 – proglumide MeSH D12.125.068.555 – lysine MeSH D12.125.068.555.478 – hydroxylysine MeSH D12.125.068.555.575 – lysinoalanine MeSH D12.125.068.555.750 – polylysine MeSH D12.125.068.665 – ornithine MeSH D12.125.068.665.340 – eflornithine
Sources: en.wikipedia.org
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.
Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.
Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.
Cardarine is a common name for GW501516, a synthetic PPARδ agonist. It is not a steroid or a selective androgen receptor modulator. It was developed and studied as a research compound for metabolic pathways.